Qnexa can help reduce sleep apnea | 
Qnexa, an experimental weight-loss drug developed by Vivus, has showed that it can reduce sleep apnea, the company confirmed last Thursday.
While the drug is marketed as a weight-loss drug, experts say that its sleep apnea applications can expand its market.
Vivus conducted a 28-week study on 45 obese patients who were suffering from sleep apnea and obstructive sleep apnea.
Treatment of Qnexa led to a significant drop in the number of apnea events for the patients.
However, there were minor side effects, like dry lips, altered taste, and sinus infections.
Vivus says that it is happy about drug’s effects on sleep apnea and plans to invest in more studies about the drug’s effects on the condition.
You must be logged in to post a comment.
Latest Headlines
- CPAP treatment is best for elderly sleep apnea patients
- Sleep apnea awareness
- Obstructive sleep apnea linked to cancer growth in mice
- Sleep apnea linked to bedwetting
- Novel therapy improves cardiovascular health in central sleep apnea patients
- Sleep apnea: a growing health concern
- Sleep Apnea Patients Unable to Tolerate CPAP Or Any Device? – A New Conservative Hope Available Now
- Insomnia linked to high insulin resistance in diabetics
- Philips displays sleep therapy products in Dubai
- The risks of sleep apnea
- AZ-TMJ – Now Reaching Even More Patients with Their Effective Sleep Apnea Treatments
- Pro baseball player gets sidelined due to sleep disorder
- The CPAP Shop Introduces New FREE eBook For CPAP Machine Users
- Sleep loss leads to greater appetite
- Sleepless elites far from grumpy and tired
In The News
Sleep loss boosts optimism and limits negative thinking
New research is looking into the
New drug funding for narcoleptic New Zealanders
Pharmac, New Zealand’s only agency under
Sleeping on your side may help prevent snoring
According to scientists, there are two
Sleep patient dies during study
What was expected to be a